BioSpace News Archive

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States, announced its unaudited financial results for the six months ended June 30, 2022.

Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding their Investigational New Drug Application (IND) for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy.

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including COVID-19, announced that on December 16, 2022 the Board of Directors appointed Charles Pope as its Chairman of the Board of Directors succeeding Dr. Frederick W. Telling, who has served as a director since June 2010 and as Chairman since February 2011.

Otonomy, Inc. announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets.

Regen BioPharma, Inc. and As 2022 comes to a close, I would like to highlight some our many accomplishments achieved this year and also to respond to the multiple queries regarding future business strategy and planning that we have received.

Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that its product, FemCath™, the first FDA-cleared intrauterine catheter for selective tubal evaluation, is now commercially available.

Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today that the first patient in the United States has been successfully treated with ShortCut™ - the world’s first dedicated device designed to split the leaflets of a pre-existing valve to enable safe Transcatheter Aortic Valve Replacement (TAVR) in patients at risk for coronary obstruction.

Reaction Biology Corporation announced that it has been selected to participate as a Specialized Center in the Chemical Biology Consortium, the discovery engine of the National Cancer Institute Experimental Therapeutics Program, administered through the Frederick National Laboratory for Cancer Research, a federal national laboratory sponsored by the NCI, part of the National Institutes of Health, and currently operated by Leidos Biomedical Research, Inc.

The global pharmacovigilance market size was exhibited at USD 9.07 billion in 2022 and it is expected to hold around USD 16.23 billion by 2030, growing at a CAGR of 7.5% from 2022 to 2030.

Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) is pleased to announce a positive recommendation from the Institut national d’excellence en santé et en services sociaux (INESSS) for RADICAVA® Oral Suspension, the oral formulation of RADICAVA® IV (edaravone), for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS).